S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
NASDAQ:TRIB

Trinity Biotech (TRIB) Stock Price, News & Analysis

$1.98
-0.04 (-1.98%)
(As of 03/27/2024 ET)
Today's Range
$1.98
$2.12
50-Day Range
$0.45
$3.09
52-Week Range
$1.85
$6.20
Volume
12,359 shs
Average Volume
15,957 shs
Market Capitalization
$15.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Trinity Biotech MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.79mentions of Trinity Biotech in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.95) to ($1.50) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.08 out of 5 stars

Medical Sector

838th out of 939 stocks

Diagnostic Substances Industry

11th out of 13 stocks

TRIB stock logo

About Trinity Biotech Stock (NASDAQ:TRIB)

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

TRIB Stock Price History

TRIB Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
TRIB Mar 2024 2.500 put
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Trinity Biotech to Present at Emerging Growth Conference
See More Headlines
Receive TRIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trinity Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/31/2024
Today
3/27/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
N/A
Current Symbol
NASDAQ:TRIB
Employees
398
Year Founded
1992

Profitability

Net Income
$-41,010,000.00
Pretax Margin
-63.91%

Debt

Sales & Book Value

Annual Sales
$74.78 million
Book Value
($0.29) per share

Miscellaneous

Free Float
6,997,000
Market Cap
$15.09 million
Optionable
Optionable
Beta
1.22

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. John Gillard (Age 43)
    President, CEO, Company Secretary & Director
    Comp: $863k
  • Mr. Ronan O'Caoimh (Age 68)
    Founder & Director
    Comp: $340k
  • Dr. James Walsh Ph.D. (Age 66)
    Executive Director of Business Development & Executive Director
    Comp: $20k
  • Mr. Des Fitzgerald
    Interim Chief Financial Officer
  • Mr. Simon Dunne (Age 50)
    Chief Accounting Officer
  • Dr. Gary Keating Ph.D. (Age 51)
    Chief Technology Officer
  • Ms. Eibhlin Kelly (Age 40)
    Chief Information Officer
  • Mr. Colm Molloy (Age 53)
    Group Director of Human Resources & Culture

TRIB Stock Analysis - Frequently Asked Questions

How have TRIB shares performed in 2024?

Trinity Biotech's stock was trading at $2.1450 on January 1st, 2024. Since then, TRIB stock has decreased by 7.7% and is now trading at $1.98.
View the best growth stocks for 2024 here
.

Are investors shorting Trinity Biotech?

Trinity Biotech saw a decrease in short interest in March. As of March 15th, there was short interest totaling 4,300 shares, a decrease of 71.9% from the February 29th total of 15,300 shares. Based on an average daily volume of 93,600 shares, the short-interest ratio is presently 0.0 days. Approximately 0.1% of the shares of the stock are sold short.
View Trinity Biotech's Short Interest
.

When is Trinity Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our TRIB earnings forecast
.

How were Trinity Biotech's earnings last quarter?

Trinity Biotech plc (NASDAQ:TRIB) issued its earnings results on Wednesday, January, 31st. The company reported ($0.90) EPS for the quarter. The business earned $14.68 million during the quarter.

When did Trinity Biotech's stock split?

Trinity Biotech's stock reverse split before market open on Wednesday, February 21st 2024. The 1-5 reverse split was announced on Wednesday, February 21st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What is Ronan O'Caoimh's approval rating as Trinity Biotech's CEO?

20 employees have rated Trinity Biotech Chief Executive Officer Ronan O'Caoimh on Glassdoor.com. Ronan O'Caoimh has an approval rating of 8% among the company's employees. This puts Ronan O'Caoimh in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Trinity Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trinity Biotech investors own include Gilead Sciences (GILD), Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Netflix (NFLX), Pfizer (PFE), QUALCOMM (QCOM), Energy Transfer (ET) and Exxon Mobil (XOM).

Who are Trinity Biotech's major shareholders?

Trinity Biotech's stock is owned by a variety of institutional and retail investors. Top institutional investors include Hunter Associates Investment Management LLC (4.27%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Trinity Biotech?

Shares of TRIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TRIB) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners